Fluidigm Announces Agreement With the University of Zurich to Distribute histoCAT for Multiparameter Imaging Mass Cytometry Data Analysis
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a distribution agreement with the University of Zurich to offer histoCAT™ software for multiparameter tissue analysis. Under the agreement, Fluidigm obtained rights to globally distribute the software in conjunction with the Hyperion™ Imaging System.
The histoCAT™ software is an innovative Imaging Mass Cytometry™ analysis toolbox that enables comprehensive analysis of cellular phenotypes and their interrelationships within the spatial context of the tissue microenvironment. Developed in the laboratory of Bernd Bodenmiller at the University of Zurich, histoCAT™ includes novel algorithms to identify the relationships and “social networks” between cells in healthy and disease states and across experimental cohorts.
The design and application of histoCAT™ were communicated in a September Nature Methods article, “histoCAT™: Analysis of Cell Phenotypes and Interactions in Multiplex Image Cytometry Data.” In this publication, Schapiro and Jackson et al. demonstrate the utility of Imaging Mass Cytometry™ combined with histoCAT™ to analyze 49 breast cancer samples, identifying cellular interaction patterns that correlated with tumor grade.
“When used together with Imaging Mass Cytometry™, histoCAT™ enables the identification of unique cellular social networks across a range of disease states,” said Bodenmiller, Assistant Professor at the University of Zurich. “By elucidating these networks in the context of clinical outcomes, histoCAT™ could improve patient classification and precision medicine applications in the future.”
“The development of histoCAT™ is a major step forward in unlocking the latent potential of mass cytometry to deeply interrogate tissue samples,” said Chris Linthwaite, President and CEO of Fluidigm. “Through this new secondary analysis software, researchers can explore a wider range of new questions in conjunction with the Hyperion™ Imaging System workflow. In collaboration with the University of Zurich, we look forward to empowering new biological insights to improve the future of health care.”
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, Hyperion, and Imaging Mass Cytometry are trademarks or registered trademarks of Fluidigm Corporation. histoCAT is a trademark of the University of Zurich.
Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the benefits and uses of the Hyperion™ Imaging System. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to uncertainties in contractual relationships and international regulated markets; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016, and in its other filings with the Securities and Exchange Commission, including Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Marketing
650 737 4190